Narayana Hrudayalaya IPO – Investors may not be Patient

  • Date 17th Dec 2015
  • Price range: Rs. 245-250 and Period: 17-21st Dec 2015
  • MidCap Rs 5100 cr Mkt Cap
  • Industry – Hospital Services
  • Advice: Avoid 

Summary

  • Narayana Hrudayalaya Ltd was founded by eminent cardiac surgeon Dr Devi Prasad Shetty in 2000. It operates a national network of hospitals, clinics and primary care facilities.
  • NHL’s revenue and EBITDA have grown 30% and 23.8% CAGR over the last 4 years. But the firm slipped into losses in FY15 on account of 3-4 acquisitions.
  • NHL delivers high quality and affordable healthcare services by leveraging economies of scale, skilled doctors, process improvements and an efficient business model.
  • However margins are low. In terms of valuations, NHL has an asking PE of over 200 times FY16 (P) which is very expensive. Thus from an investment perspective, NHL is not attractive at current IPO price points. It may however look attractive for development oriented or philanthropic investors.
  • Opinion: Investors can avoid this IPO.

IPO highlights

  • IPO is open from 17-21st Dec 2015 with Issue Price band: Rs. 245-250 per share.
  • Shares offered to public: 2.45 cr roughly of Face Value: Rs.10 per share. Market Lot: 60 shares and in multiples of 60 shares thereof. Shares offered as portion of equity post issue: 12%
  • Amount proposed to be raised: Rs. 613 cr via OFS route (there is no fresh issue of shares).
  • This IPO is a liquidity event. The shareholders exiting partially are:
Exiting Shareholders

Exhibit 1 – NHL IPO – Selling Shareholders 

Introduction to Narayana Hrudayalaya

  • NHL is a Bangalore based operator of a national network of hospitals, clinics and primary care facilities.
  • NHL had revenues, Ebitda and profits of Rs 1371.6 cr., 136.6 cr. and (-10.9) cr. resp. for FY15.
  • NHL has a network of 23 hospitals (multi-specialty or super-specialty healthcare facilities which provide tertiary care), 8 heart centers and 24 primary care facilities including clinics and information centers, across 31 locations in India. Hospitals generated 90.7% of revenue, heart centers 7.3% and all others 2%.
Facilities Network

Fig 2 – NHL’s existing and upcoming hospitals/ heart centers, source RHP

  • In FY15, NHL provided care to 19.7 lakh patients in 56 facilities with 5,442 operational beds
  • NHL’s centers provide medical care in 30 specialties, including cardiology and cardiac surgery, cancer care, neurology and neurosurgery, orthopaedics, nephrology and urology, and gastroenterology.
  • NHL has 11,163 employees, including 344 doctors, 5,587 nurses, 1,996 paramedical staff and 3,236 admin. personnel. They also have 1,750 consulting doctors engaged to their network.
  • Leadership includes Dr Devi Shetty, Chairman & ED and Dr Ashutosh Raghuvanshi, MD-CEO.
  • 3 of their hospitals are accredited by the JCI, USA for meeting international healthcare quality standards for patient care and organization management, and 6 of their hospitals are accredited by the National Accreditation Board for Hospitals and Healthcare Providers, India.
  • NHL won the “Healthcare Excellence Award for Addressing Industry Issues” in 2012 from FICCI
  • NHL won the “Arcelor Mittal Boldness in Business Award” in 2013
  • NHL received the “Outstanding Achievement Award Healthcare – Social Cause” in 2015

NHL Business News and Insights

  • NHL failed to start construction work for a proposed 1,000-bed cardiac hospital. So the state govt. issued a show cause notice to NHL initiated steps to reclaim the 6 acres of land allotted to NHL near Dumuduma (Bhubaneshwar) in Sept 2008.
  • British govt owned development finance institution CDC invested Rs 300 cr in NHL for a minority share. NHL will use the funds to expand affordable treatment in Eastern, Central and Western regions.
  • NHL raised Rs 183.9 cr. from anchor investors before the IPO opened, at the top end of pricing range.
  • The cardiac hospital in Bangalore performs about 30 heart surgeries daily, the highest in the world, at a break-even cost of Rs 1.2 lakhs. This is significantly lower cost than most other hospitals in India.
  • In line with social objectives, most patients are charged more, but the poorest are treated for free.
  • M&A: NHL acquired Westbank Hospital for Rs. 150 cr. in Nov 2014, also Asia Healthcare Development (AHDL), Meridian Medical Research & Hospital (MMRHL), and Jubilant Kalpataru Hospital in 2014.
  • NHL operates its business through a combination of the following models:
    • hospitals – that they own and operate;
    • hospitals/ heart centers – operate and pay revenue share
    • hospitals, standalone clinics and primary care facilities – operate on a lease or license basis; and
    • hospital management services provided to third parties for a fee – Managed Hospitals.
  • Dr Devi Prasad Shetty is a famous heart surgeon, who founded NHL.
  • He came to the conclusion that the health care industry needs more process innovation than product innovation. The industry “does not need a magic pill or the fastest scanner or a new procedure,” but instead requires improvements that lower the cost of medical attention and make it more widely available. Shetty’s premise of economies of scale is not radical; in fact, the doctor describes his way as “the Walmart approach.” What sets him apart, however, is that he has successfully adapted the method to a field as complex and costly as cardiac care. (knowledge@wharton).
  • NHL provides free treatment or subsidized costs to certain categories of patients. This is part of NHL’s social strategy. In some cases, their agreements with partners or state governments may also specify such quotas/ subsidies. NHL then charges higher to other patients in order to recover these costs.

Industry Outlook

  • According to WHO, India’s total expenditure on healthcare was 4% of India’s GDP in 2013. India trails developed (USA, UK) and also developing countries (Brazil, Russia, China and Thailand) on spending to GDP, due to the under penetration and price sensitivity
  • India is the 10th largest economy (GDP of USD 1.9 trillion) with 20% of the people (1.2 billion).
  • The Govt. accounted for 32.2% of healthcare expenditure in India (2013) a small increase in 10 yrs.
  • A key concern India faces is the affordability of healthcare by a vast majority of its population. According to the WHO, while 58% of the total healthcare expenditure in India is borne by consumers directly (without insurance coverage or reimbursements), this proportion rises to 86% in case of private healthcare services. This has however reduced over the last decade.
  • As per CRISIL estimates the size of the Indian healthcare delivery industry is at 3,400 million treatments in volume terms and Rs 3,80,000 cr. in value terms in 2014-15. The healthcare delivery market would grow at a CAGR of 12% till 2020.
  • Cardiac care has the highest average realization per patient (CRISIL).
Exhibit 3 – Average realization for various ailments, Source RHP, JainMatrix Investments

Exhibit 3 – Average realization for various ailments, Source RHP

  • A key cost factor in a hospital is the initial capital outlay required, particularly for land, building development and equipment. The capital cost to build a hospital is typically Rs 70-80 lakhs per bed (for a typical 200 bed multispecialty hospital, excluding land costs).
  • The drivers of growth in the healthcare delivery market in India are:
    • Potential in bed capacity – India’s bed density is 7/10,000 people (global median – 27 beds).
    • Govt spending on healthcare will remain low, allowing private sector to increase presence
    • Increasing population as well as life expectancy to require greater health coverage
    • Rising income levels to make quality healthcare services more affordable
    • Growth in medical tourism, cosmetic medical services to aid demand growth
  • Anecdotal evidence points to falling medical standards in large hospitals:
    • Cesarean births are rising alarmingly as a ratio to natural deliveries in many regions.
    • Many large urban hospitals target affluent patients with a battery of unnecessary tests and procedures, effectively milking the patient under the guise of a doctor’s line of treatment.
    • Medical services are only as good as the person serving you. Stories abound of medical negligence like silly errors during operations, nurses and staff missing pre or post operation, etc.
    • Inflated medical bills for patients with insurance
  • There appears to be a shortage of medical nursing staff. This is attributed to a lack of professional growth in India (and ample opportunities abroad). Nurses in India are not allowed to carry out simple medical tasks, which are reserved for doctors, thus limiting their professional growth.
  • Medical Colleges and higher education are constrained by limited seats and high costs.
  • Many such issues fall under the purview of the Medical Council of India.

Financials of NHL

  • The EPS of NHL has grown 32.5% CAGR from the year 2011-2014 which is a positive sign of high growth potential. However in FY15 NHL posted a loss of Rs 10.9 cr. Also again it has turned PAT positive for HI FY16. Note FY16P data is a simple doubling of H1 data.
  • NHL’s revenue and EBITDA has grown 30% and 23.8% CAGR over the last 4 years. This is excellent.
  • Margins have become thinner for NHL in the last 4 years. See Fig 4.
Fig 4 – NHL Financials, JainMatrix Investments

Fig 4 – NHL Financials, JainMatrix Investments

  • NHL has been operating cash positive over 5 years, but the free cash flows are negative. Fig 5.
Fig 5 – NHL cash flow, JainMatrix Investments

Fig 5 – NHL Cash Flow

Positives for the IPO

  • NHL has a social commitment to provide subsidized/free services to some patients.
  • Dr Devi Shetty has through NHL created a ‘Walmart’ type business model for high end services like heart surgeries, and has lowered costs while delivering high quality. This is widely recognized in the industry and NHL/ Dr Shetty have been awarded many times for these achievements.
  • NHL has a strong brand ‘Narayana Health’ with good presence in Karnataka & East India. Its has a reputation for clinical excellence and affordable healthcare.
  • NHL is setting up in the NorthEast and Vaishno Devi (where hospital facilities are scarce), Lucknow (multi-specialty hospital), Mumbai (pediatric hospital) and Bhubaneshwar (tertiary care).
  • NHL is strong in many segments, but particularly in cardiology and cardiac surgery.
  • Capital efficiency – NHL’s capital cost is Rs 25.5 lakhs/bed in FY2015 (industry avg 70-80 lakhs/ bed).
  • Ability to attract high quality doctors and medical support staff.
  • Experienced management team with a strong execution track record.
  • Anecdotal evidence suggests that the NHL chain appears to have a better reputation in terms of patient care, good medical advice and trustworthy services than other large hospital chains.

Internal Risks 

  • Dr Devi Shetty has built NHL to this scale, but there may be a need to broad base the firm’s leadership so that it can become an institution, rather than be dependent on a few leaders.
  • Just three large hospitals contribute 58% of total revenues currently. Thus any disruption to any of these 3 will affect their business.
  • A majority of NHL doctors are not employees but medical consultants. There is no assurance that they would continue to provide services to NHL on an ongoing basis. This can affect business.
  • NHL has in the past ceased operations and decommissioned beds at some facilities. NHL may not be able to successfully implement all their growth strategies, particularly in Tier II and Tier III cities.
  • Litigation related to medical services, from patients is a business risk.
  • They recently acquired a third party hospital and two hospitals companies. These and any future acquisitions may present integration challenges or turn out to be unprofitable. Acquisitions carry the inherent risk of past non-compliance and undisclosed liabilities.
  • NHL is exposed to business risks related to clinical trials undertaken and stem cells they preserve.
  • The IPO is a liquidity event and an exit platform. Funds raised will not benefit NHL.

External Risks

  • In general, a number of govt. and regulatory registrations, licenses and approvals have to be obtained. In particular, Narayana Hospitals and AHDL have not obtained occupancy rights over certain hospitals and clinics they operate out of, and not obtained ownership rights over certain lands forming part of NH Health City and certain superstructures constructed by them in RTIICS. They run the risk of being dispossessed of these properties. (RHP)
  • The Central or State Governments may exercise rights of eminent domain in respect of the land on which NHL’s facilities are situated.

Benchmarking

In a benchmarking exercise, we compare NHL with some listed peers.

Exhibit 6 - Benchmarking, JainMatrix Investments

Exhibit 6 – Benchmarking, JainMatrix Investments

  • Sales at NHL have shown an impressive growth.
  • But valuations look expensive. Since there was a loss in FY15, the PE is not mentioned. But estimated PE for FY16 falls in the 200-205 range, a very high number.
  • Even on EV/EBITDA and EV/ Sales, NHL falls at the higher end among its peers.
  • Debt levels are reasonable, not high. But return ratios are quite low.
  • The reason we can find for low margins and even losses in FY15 are – several acquisitions were made in this year, which are integral with NHL’s growth strategy. However these operations are yet to contribute to the returns for NHL.

Overall Opinion

  • India with its large and growing population is badly stretched in terms of quality healthcare facilities. Expenditure in this sector will trend upwards. Govt’s (free) facilities cater to the low end of market.
  • NHL has a good brand name and sustainable model for providing quality and affordable healthcare. It has lowered the costs of delivering complex procedures, while also meeting social objectives.
  • The pricing for NHL IPO looks stretched from various angles. In FY 2015, NHL suffered a loss. At the projected FY16 profits, the PE looks like 200-205 times.
    • Perhaps NHL has in an attempt to grow fast and acquire companies, compromised on profits for FY2015 and FY2016. Modern companies are making such trade-offs.
    • Perhaps NHL has sacrificed profits for its social objectives. It can easily improve margins but takes on a number of free or subsidized procedures and ‘does good rather than just make money’.
    • Can the trustworthiness and technical competence at NHL justify a big pricing premium to the peers in Exhibit 6?
  • NHL does not have positive free cash flows since 5 years.
  • NHL executives need to clearly articulate their profit or social objectives to potential investors and shareholders, especially since these clash with each other.
  • We conclude from this that for investors, NHL is not attractive at current price points. But it may look attractive for development oriented or philanthropic investors.
  • Investors should avoid this IPO and look to enter the counter at lower levels.

READ AND DOWNLOAD THE ENTIRE REPORT

Here is a note on the NHL IPO in PDF format.

JainMatrix Investments_Narayana Hrudalaya IPO_Dec 2015

Click the link above to open/ download the PDF document.

JAINMATRIX KNOWLEDGE BASE 

See other useful reports

  1. Track Record – Dec 2015
  2. Dr Lal Pathlabs IPO
  3. Alkem Labs IPO
  4. Goods And Services Tax (GST): Integration And Efficiency
  5. Indigo IPO – Flying High, Wide And Handsome
  6. Café Coffee Day IPO – Very Hot Coffee 
  7. Syngene IPO: Good Pharma R&D spinoff from Biocon.
  8. Navkar Corp IPO – Location Challenges – Avoid
  9. CPSE ETF – Unlocking Value, Slowly
  10. JainMatrix IPO Reports deliver 60.5% returns

Search for companies/ sectors of your interest in Search box in the right panel.

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports

Do you find this site useful?

  • Visit the Investment Servicepage to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in Narayana Hrudalayala Ltd. or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

Dr Lal Pathlabs IPO – Essential Services are an Essential Buy

  • Date 9th Dec 2015
  • Price range: Rs. 540-550 and application period: 8-10th Dec
  • Industry: Pharma – Diagnostic services
  • Mid Cap – Rs 4550 cr Mkt Cap 
  • Advice: Retail Investors can BUY with a 2-3 year perspective

Summary

  • Overview: DLP is provider of diagnostic and related healthcare tests and services.
  • DLP’s Revenue, EBITDA and EPS have grown at 29.2%, 29% and 33.9% CAGR over 4 years.
  • Key strengths are a proven, robust ‘hub and spoke’ model which allows consistent service levels and rapid growth. It is the #2 player in this space, with a strong North India presence. It has a good brand in this niche, which can be leveraged. DLP’s model is scalable; its reach can be expanded rapidly. Also it’s not a discretionary service, more like an essential service.
  • In terms of valuations, DLP has an asking PE of 54.5 times FY16 (P) which looks expensive. However we feel that the business can be valued closer to retail food services than hospitals.
  • As an investment, the DLP IPO is rated a medium risk, high return type of offering.
  • Opinion: Investors can subscribe to this IPO for a 2-3 year perspective.

Here is the investment note on Dr Lal Pathlabs (DLP).

IPO highlights

  • IPO is open from 8-10th Dec 2015 with Issue Price band: Rs.540-550 per share
  • Shares offered are 1.16 cr. of FV: Rs. 10 per share, and amount to be raised: Rs.638 cr. via OFS route. Shares offered as portion of equity post issue: 14.1%.
  • Market Lot: 20 shares and in multiples of 20 shares thereof.
  • There is a Rs 15 discount for Retail.
  • Objects of the issue: Promoters, promoter group and investors are exiting partially from their investments. No funds raised in IPO will benefit the company directly.
  • The promoter stake will reduce from 63.7% to 58.7% post IPO. Also the Pre IPO shareholding of the private investors/ VCs was 32.2% which would get reduced to 23.2% once the shares get listed.

Introduction

  • DLP is a Delhi based provider of diagnostic and related healthcare tests and services.
  • DLP had revenues, EBITDA and profits of Rs 662 cr, Rs 158.9 cr and Rs 95 cr. in FY15.
  • DLP’s network includes National Reference Lab in New Delhi, 171 clinical labs, 1,554 patient service centers and 7,000 pickup points. Network is all India, but unevenly spread, see Fig 1-2.
  • Customers include individual patients, hospitals, other healthcare providers and corporates.
  • DLP is staffed with 3,253 full-time employees and 83 full-time consultants (contractual).
  • DLP has built a national, “hub and spoke” network. Specimens are collected across multiple locations in a region for delivery to a designated clinical laboratory for centralized diagnostic It provides them with greater economies of scale and is the platform for good growth.
  • DLP provides has over 3,495 diagnostic and related healthcare tests and services including – Routine clinical lab tests (blood chemistry analyses and blood cell count), Specialized testing (histopathology, genetic marker, viral and bacterial cultures and infectious disease); and Preventive testing services (screenings for hypertension, heart disease and diabetes).
  • DLP was started by late Dr. Major S.K. Lal in 1949, by providing pathology services and maintaining a blood bank. The current leadership is Brig. Dr. Arvind Lal (CMD), Dr. Vandana Lal (Dir.), Dr. Om Prakash Manchanda (Dir & CEO) and Mr. Dilip Bidani (CFO).
  • The Pre IPO shareholding of private investor/ shareholders was 32.2% which would get reduced to 23.2% post IPO. Private equity/ VC investors like Wagner Ltd., WestBridge Crossover Fund, LLC and Sanjeevini Investment Holdings are associated with DLP.
  • The key strategy of DLP is to continue to expand their presence in the markets in which they operate and also into other markets in India through strategic acquisitions and partnerships.
  • For FY15, 72% of the revenues were from the Northern region. Currently the focus of the company is to strengthen and expand their presence in Central and Eastern India. A new large, regional reference laboratory is under construction in Kolkata.
Fig 1 - Revenue Segments, JainMatrix Investments

Fig 1 – Revenue Segments, JainMatrix Investments

Fig 2 – Service Network, Source DRHP

Business News and Updates

  • DLP had announced its plan to expand operations in Bengaluru through new centers and labs to reach a total number of 50 centers (from current 20) by Dec 2015.
  • BD India and DLP inaugurated a Centre of Excellence in Phlebotomy (blood collection, sampling) in June 2015. This center was launched to provide certified phlebotomy courses to healthcare professionals, and improving best practices for accurate and reliable diagnosis.
  • DLP had acquired Ashish Pathology Labs, a lab in Ahmedabad as part of its acquisition strategy to expand inorganically last year. It has been growing mainly through organic expansion. In northern, eastern and central India it has been adding 20-25 labs year on year.
  • As per DLP, “each lab costs around Rs 1 crore and there are additional investments in facilities like IT among others. Overall, we invest Rs 40-50 crore for our expansion every year”.
  • DLP has sample collection centers in 9 countries and plans to start in Africa with Nigeria.
  • Per latest data, DLP on day 2 of IPO is 2.65 times subscribed a sign of good success.

Industry Outlook

  • According to the World Health Organization (WHO), India’s total expenditure on healthcare was 4% of the GDP as of 2013. India trails both developed countries (USA, UK) and also developing countries (Brazil, Russia, China and Thailand) in healthcare spending % of GDP. This is due to the under penetration of healthcare services as well as partial govt. ownership.
  • As per CRISIL Research, the Indian diagnostics industry is at Rs 37,700 cr. in FY15. It will continue to grow by 16-17% CAGR over the next three years to over 60,000 cr. by FY18.
  • Demand drivers for the Indian diagnostic industry include:
    • Increase in evidence-based treatments; Changing disease profiles; big demand-supply gap;
    • Increase in health insurance coverage; Need for greater health coverage as population and life expectancy increase; Rising income levels make quality healthcare services affordable
    • Growing demand for lifestyle diseases-related healthcare services
  • Urban areas account for a higher proportion of revenues in diagnostics industry, as the urban population (28% of population) contributes 67% of revenues (CRISIL Research).
  • DLP trails only Fortis Healthcare controlled SRL in the diagnostics business. SRL had acquired Piramal Diagnostics to become the top player in the industry four years ago.
  • The Govt. accounted for 32.2% of healthcare spends in India (2013), a small increase in 10 yrs.

Financials of DLP

  • DLP’s Revenue, EBITDA and EPS have grown at 29.2%, 29% and 33.9% CAGR over 4 years.
  • This is excellent as it indicates that the business is in high growth mode. Even with increasing competition and declining margins, the performance looks good. See Fig 3.
Fig 3 - Pathlabs Financials, JainMatrix Investments

Fig 3 – Pathlabs Financials, JainMatrix Investments

  • However H1FY16 results were disappointing and the projected EPS for FY16 is Rs 10.1, whereas it was Rs 11.5 for FY15. This is a negative sign. Note FY16P data is a simple doubling of H1 data, also accounting for one time/ exceptional charges related to IPO.
  • Currently DLP has zero outstanding borrowings as well as term loans. This is a big plus from the financial perspective. DLP has the option to raise funds in future if required.
  • The operating margins have declined to 24% from 25.5% in 2012. However the profit margins have improved from 12.4% in 2011 to 14.3%. But Profit margins fell in H1FY16 to 9.2%.
  • DLP’s operations have been both operating and free cash flow positive since 5 years. This is positive. But there is a declining trend due to increasing investments in the business. Fig 4.
Fig 4 - Cash Flow, JainMatrix Investments

Fig 4 – Cash Flow, JainMatrix Investments

Positives for Dr Lal Pathlabs and IPO:

  • DLP financials have shown strong growth in 4 years. DLP has been acquiring small medical labs to grow inorganically. Such growth is also sustainable.
  • DLP has a strong footprint in the North. Expansion in South & East will give a further impetus.
  • They have built a good brand in diagnostics which is likely to strengthen in the near future.
  • DLP uses a ‘Hub and Spoke’ business model, which allows consistent service levels and rapid growth.
  • Experienced leadership team includes professionals with strong industry expertise and track record.

Internal Risks

  • The Dr Lal PathLabs brand is fundamental to their business, and any failure to maintain the quality of their diagnostic healthcare services provided could affect their business.
  • Business interruptions at DLP’s National Reference Laboratory may also affect operations.
  • DLP’s business depends on franchisees and business partners. Any non-performance by them may adversely affect DLP. Some of their lab operations are undertaken jointly with third parties, whose interests may differ from DLP’s, and such arrangements entail certain risks.
  • DLP leases the majority of its laboratories and other business premises. They might not be able to renew any such leases on favorable terms, and costs will rise.
  • DLP is subject to seasonal fluctuations in operating results and cash flows. Diagnostic healthcare testing volumes typically increase during the monsoon season and experiences slower business during Dec-Jan, when the temperature and humidity are lower.
  • For DLP, the employee benefit expenses have risen sharply over the last 5 year reflecting shortages in medical / doctor staff. If this accelerates, it can impact profitability.

External Risks

  • DLP operates in a competitive business environment which has low barriers to entry.
  • Diagnostics business is still dominated by unorganized local centers rather than large chains.
  • The business is subject to a variety of central and state govt taxes and surcharges, and any increase in tax rates — such as GST, could adversely affect their financials.
  • Political instability or disruptions at locations where they operate can affect business.

Benchmarking

Exhibit 5 - Benchmarking, JainMatrix Investments

Exhibit 5 – Benchmarking, JainMatrix Investments

We compare DLP with hospital chains as well as retail focused service companies:

  • DLP emerges quite strongly across parameters like margins, growth, and return ratios.
  • It does not lead the pack on the valuation parameters.
  • Based on this it appears that the valuations of DLP may fall somewhere between established hospital chains and the leading retail service business.

Overall Opinion

  • India with its large and growing population is stretched in terms of available healthcare facilities. Expenditure in this sector will trend upwards. Govt’s (free) facilities cater to the low end of market.
  • In this space, DLP’s diagnostic and healthcare services provide an essential, high demand service. Its not a discretionary service, more like an essential service.
  • The business model is robust and scalable, and there are clear benefits of a national chain over small and local service providers.
  • DLP has a good brand and solid service delivery in the North, where it is established. We believe that DLP will be able to grow and roll out a national (urban) footprint. The next target would be semi urban and rural areas. There is massive potential to grow over the next 10 years.
  • In terms of valuations, DLP has an asking PE of 54.5 times FY16 (P) which looks expensive. However we feel that the business can be valued closer to a retail food service than a hospital. DLP’s model is scalable; its reach can be expanded rapidly.
  • As an investment, the DLP IPO is rated a medium risk, high return type of offering.
  • Retail Investors can BUY this IPO with a 2-3 year perspective.

READ AND DOWNLOAD THE ENTIRE REPORT

Here is a note on the Dr Lal Pathlabs IPO in PDF format.

JainMatrix Investments_Dr Lal PathLabs IPO_Dec 2015

Click the link above to open/ download the PDF document.

JAINMATRIX KNOWLEDGE BASE 

See other useful reports

  1. Alkem Labs IPO
  2. Goods And Services Tax (GST): Integration And Efficiency
  3. Indigo IPO – Flying High, Wide And Handsome
  4. Café Coffee Day IPO – Very Hot Coffee 
  5. Syngene IPO: Good Pharma R&D spinoff from Biocon.
  6. Navkar Corp IPO – Location Challenges – Avoid
  7. CPSE ETF – Unlocking Value, Slowly
  8. JainMatrix IPO Reports deliver 60.5% returns

Search for companies/ sectors of your interest in Search box in the right panel.

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports

Do you find this site useful?

  • Visit the Investment Servicepage to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

Disclaimer

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. JM has no known financial interests in Dr Lal Pathlabs Ltd. or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com

A View on the Indian Rupee

THOUGHT FOR THE DAY:

The Indian rupee has been weakening against the USD over time. The graphic provides one month and 5 year charts.

Charts

ExchangeRateHistory

INR to USD rates (chart credits dollars2rupees.com) 

The 5 year low for INR was 67.09 to a dollar hit in Aug 2013, in the wake of the USA Quantitative tightening scare. At that time our USD reserve holdings were low, and the market went through a period of panic and uncertainty. Thereafter, we have seen a steadiness of the INR, even though it continues to weaken against USD. We are now just 1% away from this past low.

If we look at this 5 year period, we can see that the INR weakened in this period by 47.69% absolute. This translates into 9.54% simple average, and 8.11% CAGR weakening per year.

Exchange Factors

The exchange rate is a complex function of factors such as:

  1. Trade deficit in India. Net investments including FII and FDI, remittances and outflows.
  2. Fiscal performance of Indian government.
  3. Inflation and GDP growth.
  4. Forex reserves, risk perceptions and trade outlook.

INR Outlook

  • The rise in interest rates indicated by the US Fed for Dec 2015 is another important event. If it comes through (it’s been postponed several times) it will result in some USD flowing back to USA to earn higher returns with low risk.
  • But overall India is well placed to defend its currency. On most of the factors named above, India is doing better now than in the past 5 years. My feeling is that the INR weakening of 8.1% CAGR seen in recent years should slow down to 4-5% over the next 5 years.
  • Exports from India remains an important theme in our investment portfolios, given the small base and massive potential. Sectors riding this theme are IT services, pharma and auto ancillaries.

JAINMATRIX KNOWLEDGE BASE:

See other useful reports:

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

 

GST: Integration and Efficiency

THOUGHT FOR THE DAY:

GST is in the news a lot these days. Lets look at this new initiative in a little detail:

What is GST in India?

GST (Goods and Service Tax) is a comprehensive indirect tax that would be levied on manufacture, sale and consumption of goods and services at a national level. It will replace multiple taxes like CENVAT, central sales tax, state sales tax, octroi, etc. It would be levied whenever a consumer buys goods or services.

The government plans to roll out GST from April 1, 2016. Much depends on the legislative discussions and approvals. The delay in recent years in passing the GST bill has been in part due to political wrangling between the parties in power at the center, and the opposition.

efficiency

Benefits and impact of GST?

The tax sharing formula is such that big consumer states such as UP, West Bengal and Kerala will get a high share of the taxes, while the producer states such as Tamil Nadu, Maharashtra and Gujarat may lose out on revenues. To compensate, the bill provides for 1% extra tax on goods for at least two years. This extra revenue will go to the producer state. When introduced, GST will not only make the tax system simpler, but will also help increased compliance, boost tax revenues, reduce the tax levies on consumers and make exports competitive.

GST will boost the pan-India market by eliminating inter-state tax paperwork, delays in checks on state orders and stabilize prices across regions. Experts expect this to lift the country’s GDP by 1-2%.

What would be exempt from GST?

Petroleum products, potable alcohol and tobacco have been kept out of the purview of the GST. The center and the states have agreed to restrict number of exemptions to 100. All the goods and services not in this list would be taxed.

Sectors that will benefit:

  • We feel that FMCG, pharma, power sector, logistics and auto and auto ancillaries would be the sector gainers from GST implementation.
  • More than any specific sector, we feel that GST getting legislative approvals would be a confidence booster for the markets and a reforms related achievement for the central government.

JAINMATRIX KNOWLEDGE BASE:

See other useful reports:

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

 

Power Sector – A Complex Challenge

THOUGHT FOR THE DAY:

The Power sector of India presents a complex set of challenges. On one hand there is no doubt that a 6-8 % growth in GDP also needs 10% growth in power supply. On the other hand, many plants set up recently are not able to supply power. Lets look at the challenges:

  • Power generation capacity – is not the main challenge. Recent programs by GoI have resulted in good and sufficient capacity increases.
  • Power distribution firms weak – The Discoms are short of funds. State wise decisions like low tariffs, free power to agriculture, T&D losses, etc have rendered discoms weak financially.
    • Power Minister Piyush Goyal announced a scheme for turning around discoms , reeling under a combined debt of more than Rs 4.2 lakh crore. Under the scheme, called the Ujwal DISCOM Assurance Yojana (UDAY ), the states will take over 75% debt of their discoms and, in return, get leeway to borrow more. So there is a ray of hope for discoms.
  • T&D losses are huge: Per a recent report almost 25% of the power generated is lost, and never gets billed for — double the global average of about 12%. This problem needs a combination of political will and tough implementation/ law and order, to plug leakages.
Embed from Getty Images
  • Fuel linkage issues: Power plants are set up, but the fuel, be it gas or coal, is not supplied in good quantity or at the right price. New Gas supply expected from Indian E&P firms has not materialized. High LNG prices till end 2014 rendered it uneconomic for power sector.
    • The GoI is attempting to solve this for Coal by setting up agreements between Coal India and large important consumers. Coal India has also increased production recently, improving supplies and reducing the need to import coal.
    • LNG gas scenario may change rapidly after the Qatar Gas – Petronet LNG renegotiation. Spot LNG prices in Asia have also fallen 50% in the last one year.
  • Power evacuation: Some states and regions are surplus in power, and others deficit. Not enough has been invested in a good power grids. Southern states are power deficit.
    • The govt. is inviting bids for transmission projects worth Rs 12,000 crore soon, to address the congestion in supply lines to South and East India.
  • Pollution: Power gen through fossil fuels also creates air pollution and particulate matter.
    • Renewables – solar and wind power, are getting a massive stimulus by government that is trying to build the solar generation ecosystems and is targeting a deployment of 20,000 MW of grid connected solar power by 2022.

From an investment perspective, we are positive on a few firms from the Power – Transmission & Equipment pack.

With the recent economic slowdown, we sense that even though the power deficit has reduced, many consumers are still facing power cuts and poor quality power supply. Lets hope that these new initiatives by the government address and resolve the problems in the power sector.

JAINMATRIX KNOWLEDGE BASE:

See other useful reports:

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

 

PSUs are HOT investments

The government sector and PSUs were, till recently, not very good investments. The reasons were many. There was an uncertainty about their future.

Now things have changed:

  • The new Central government (well not new, now about 18 months in power) has undertaken a number of structural reforms that will slowly but surely improve the economy.
  • Government departments, lead by motivated ministers, are gathering speed in terms of clearer objectives, faster decisions and accountability. Coordination issues among ministries are being sorted out.
  • There are plans emerging for PSUs disinvestment, which will accelerate this process.
  • The slogan is ‘less government, more governance’. They appear to be executing on this.

In the light of this, JainMatrix Investments has prepared a report on a mid sized PSU. Based on our research, the PSU firm has a projected 80% gain in 2 years.

This is however premium content, so we invite you to subscribe to our Investment service to receive this and other such reports.

THE INVESTMENT SERVICE SUBSCRIPTION – Click Link to get the details

 

JainMatrix Knowledge Base:

See other useful reports:

 

 

Do you find this site useful?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.

 

SKS Microfinance – a Magical Mix

  • Date: 01st Sept, 2015
  • CMP: Rs 457
  • Mid Cap – with Mkt Cap of Rs 5800 crores
  • Advice: High risk, high return stock, BUY
  • Target: Rs 844 by Mar 2017, an 85% appreciation

Summary

Overview: SKS Microfinance is a leader in small business loans for low income people in rural and village areas. State policy changes in AP in 2010 affected operations and SKS plunged into losses. But now the recovery is complete. Total income, NII (Net Interest Income) and Net Profit have grown at 24%, 22% and 36% CAGR over the last 7 years. NPA levels are quite low.

Why buy now: 1) SKS has a magical mix of Social Service and Good Business. 2) It’s a turnaround opportunity that is stabilizing now, and the firm should be able to grow at 40% CAGR over the next 2 years 3) In a recent correction, it has fallen 22% in the last month from a recent high.

The rest of this report is available on this LINK – JainMatrix_SKS Aug 2015

DISCLAIMER

This document has been prepared by JainMatrix Investments Bangalore (JM), and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of JM. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, JM has not independently verified the accuracy or completeness of the same. Punit Jain has a personal shareholding in SKS since Nov 2014. Other than this, JM has no known financial interests in SKS or any related firm. Neither JM nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient’s particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. JM has been publishing equity research reports since Nov 2012. JM has applied for certification under SEBI (Research Analysts) Regulations, 2014. Any questions should be directed to the director of JainMatrix Investments at punit.jain@jainmatrix.com .

JAINMATRIX KNOWLEDGE BASE:

See other useful reports

Visit and Like JainMatrix FB or Follow on JainMatrix Twitter for reports.

Check back on the website jainmatrix.com for updates.

DO YOU FIND THIS SITE USEFUL?

  • Visit the Investment Service page to find how you can get more. Or Click LINK
  • Register Now to get our Free reports and much more, on the top right of this page, or by filling this Signup Form CLICK.